Skip to main content
. 2020 Sep 15;10:15086. doi: 10.1038/s41598-020-72155-8

Figure 7.

Figure 7

Olaparib treatment results in increased PARP1 binding and decreased MyoD recruitment to p57 and myogenin regulatory regions. ChIP-qPCR analysis for PARP1 and MyoD binding to KvDMR1 and myogenin promoter (MyoG prom). Samples were prepared from C2.7 cells collected 24 h after the shift to differentiation medium in the presence of either 1 µM Olaparib or the control vehicle DMSO (VEHICLE), and then immunoprecipitated as described in Fig. 4. Protein binding is expressed as percentage of input and represents the mean ± SEM of three independent experiments. Statistical significance: p-value < 0.05 (*).